JP2014523742A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523742A5 JP2014523742A5 JP2014519581A JP2014519581A JP2014523742A5 JP 2014523742 A5 JP2014523742 A5 JP 2014523742A5 JP 2014519581 A JP2014519581 A JP 2014519581A JP 2014519581 A JP2014519581 A JP 2014519581A JP 2014523742 A5 JP2014523742 A5 JP 2014523742A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tau
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013498 tau Proteins Human genes 0.000 claims description 106
- 108010026424 tau Proteins Proteins 0.000 claims description 106
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 72
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 72
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 208000034799 Tauopathies Diseases 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 230000026683 transduction Effects 0.000 claims description 10
- 238000010361 transduction Methods 0.000 claims description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 229920002307 Dextran Polymers 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 108091006106 transcriptional activators Proteins 0.000 claims description 4
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 claims description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- -1 polyethylamine Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 108700031308 Antennapedia Homeodomain Proteins 0.000 claims description 2
- 101150019028 Antp gene Proteins 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 2
- 101150048348 GP41 gene Proteins 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010088535 Pep-1 peptide Proteins 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 101710192266 Tegument protein VP22 Proteins 0.000 claims description 2
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 239000000126 substance Substances 0.000 claims 8
- 230000000975 bioactive effect Effects 0.000 claims 2
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 33
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- JMBLPSUDFRAOLU-UHFFFAOYSA-N 1-[6-amino-2-[[2-[[2-[2-[[1-[2-[[2-[[2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]propanoylamino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl Chemical compound C1CCC(C(O)=O)N1C(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C)NC(=O)C1CCCN1C(=O)C(CO)NC(=O)C(CC(O)=O)NC(=O)CNC(=O)C(N)CCCN=C(N)N JMBLPSUDFRAOLU-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1112056.5 | 2011-07-14 | ||
| GBGB1112056.5A GB201112056D0 (en) | 2011-07-14 | 2011-07-14 | Antibodies |
| PCT/EP2012/063924 WO2013007839A1 (en) | 2011-07-14 | 2012-07-16 | Antibodies to phosphorylated tau aggregates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523742A JP2014523742A (ja) | 2014-09-18 |
| JP2014523742A5 true JP2014523742A5 (enExample) | 2015-09-03 |
| JP6168364B2 JP6168364B2 (ja) | 2017-07-26 |
Family
ID=44586547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519581A Active JP6168364B2 (ja) | 2011-07-14 | 2012-07-16 | リン酸化タウ凝集体に対する抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9447179B2 (enExample) |
| EP (1) | EP2731969B1 (enExample) |
| JP (1) | JP6168364B2 (enExample) |
| AU (1) | AU2012282402B2 (enExample) |
| GB (1) | GB201112056D0 (enExample) |
| WO (1) | WO2013007839A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| KR101973063B1 (ko) | 2011-04-06 | 2019-04-30 | 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 지질-기반 나노입자들 |
| WO2013110013A1 (en) | 2012-01-20 | 2013-07-25 | Annapragada, Ananth | Methods and compositions for objectively characterizing medical images |
| NZ703423A (en) | 2012-07-03 | 2018-02-23 | Univ Washington | Antibodies to tau |
| SG10201701181XA (en) * | 2012-08-16 | 2017-04-27 | Ipierian Inc | Methods of treating a tauopathy |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| CU24446B1 (es) | 2013-03-13 | 2019-10-04 | Prothena Biosciences Ltd | Un anticuerpo monoclonal humanizado que se une a tau |
| EA039554B1 (ru) * | 2013-06-10 | 2022-02-09 | АйПИЕРИАН, ИНК. | Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости |
| JP6629201B2 (ja) * | 2013-11-27 | 2020-01-15 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| AU2014368696A1 (en) | 2013-12-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Humanized anti-Tau(pS422) antibodies and methods of use |
| EP2899208A1 (en) * | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof |
| JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| MX371295B (es) | 2014-10-08 | 2020-01-24 | Texas Childrens Hospital | Formación de imágenes por irm de placas amiloides usando liposomas. |
| WO2016055941A1 (en) * | 2014-10-10 | 2016-04-14 | National Research Council Of Canada | Anti-tau antibody and uses thereof |
| AR103713A1 (es) | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
| NZ737796A (en) * | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| JP6619460B2 (ja) | 2015-06-24 | 2019-12-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ヒト化抗タウ（ｐＳ４２２）抗体及び使用法 |
| MX2017015908A (es) | 2015-07-06 | 2018-03-15 | Ucb Biopharma Sprl | Anticuerpos de union a tau. |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US10752679B2 (en) | 2016-05-02 | 2020-08-25 | Prothena Biosciences Limited | Tau immunotherapy |
| EA201892417A1 (ru) | 2016-05-02 | 2019-05-31 | Протена Биосайенсис Лимитед | Антитела, распознающие тау |
| AU2017259039B2 (en) | 2016-05-02 | 2024-05-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CA3030754C (en) * | 2016-07-20 | 2022-04-26 | Anahit Ghochikyan | Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| KR101876423B1 (ko) | 2016-10-10 | 2018-07-09 | 한국과학기술연구원 | 치매 모델 형질전환 마우스 및 이를 이용한 스크리닝 방법 |
| FR3058143B1 (fr) * | 2016-10-27 | 2021-03-12 | Univ Grenoble Alpes | Nanocorps anti-tau |
| EP3551220B1 (en) | 2016-12-07 | 2025-01-29 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| JP2020511937A (ja) | 2016-12-07 | 2020-04-23 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| MX2019009817A (es) | 2017-02-17 | 2019-11-21 | Denali Therapeutics Inc | Anticuerpos anti-tau y metodos de uso de los mismos. |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| PE20210115A1 (es) | 2017-10-16 | 2021-01-19 | Eisai Randd Man Co Ltd | Anticuerpos anti-tau y uso de los mismos |
| IL302108A (en) * | 2017-10-25 | 2023-06-01 | Ac Immune Sa | Preparations of phosphorylated tau peptides and uses thereof |
| AU2019232631A1 (en) | 2018-03-05 | 2020-09-24 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
| US10591492B2 (en) * | 2018-03-05 | 2020-03-17 | Janssen Pharmaceutica Nv | Assays to detect neurodegeneration |
| JP2021530552A (ja) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
| JP7594913B2 (ja) * | 2018-11-22 | 2024-12-05 | 富士レビオ株式会社 | 抗体コンジュゲート |
| WO2020120644A1 (en) * | 2018-12-13 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New anti tau svqivykpv epitope single domain antibody |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| JP2024534348A (ja) | 2021-09-09 | 2024-09-20 | アルツパス， インコーポレイテッド | ホスホ－タウ抗体および使用の方法 |
| CN119661705B (zh) * | 2024-11-22 | 2025-06-24 | 上海伯杰医疗科技股份有限公司 | 一种抗p-Tau217蛋白单克隆抗体及其制备方法和应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| DE69233367T2 (de) | 1991-04-10 | 2005-05-25 | The Scripps Research Institute, La Jolla | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| EP0610330B1 (en) | 1991-10-25 | 1997-06-18 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau |
| DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| ATE335007T1 (de) | 1993-12-21 | 2006-08-15 | Innogenetics Nv | Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen |
| ES2247204T3 (es) | 1994-01-31 | 2006-03-01 | Trustees Of Boston University | Bancos de anticuerpos policlonales. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| ES2294799T3 (es) | 1996-06-27 | 2008-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana. |
| US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| US8871447B2 (en) | 2002-09-12 | 2014-10-28 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
| US7238788B2 (en) * | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| AU2005269940A1 (en) | 2004-07-02 | 2006-02-09 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid beta (Abeta) |
| JP4820757B2 (ja) | 2004-08-11 | 2011-11-24 | 国立大学法人京都大学 | 抗体及びその利用 |
| JP5173426B2 (ja) | 2004-10-25 | 2013-04-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ａｄｄｌ抗体およびこの使用 |
| CA2630964A1 (en) | 2005-11-22 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Antibody treatment of alzheimer's and related diseases |
| JP5161796B2 (ja) | 2006-02-24 | 2013-03-13 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | 抗アミロイド免疫原性組成物、方法、および使用 |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| WO2008070229A2 (en) * | 2006-08-28 | 2008-06-12 | Case Western Reserve University | Detection of pathogenic aggregates of protein in a sample by homologous elisa |
| TW200844110A (en) | 2007-01-11 | 2008-11-16 | Univ Marburg Philipps | Diagnosis and treatment of alzheimer's disease and other neurodementing diseases |
| TWI557136B (zh) * | 2007-06-12 | 2016-11-11 | Ａｃ免疫公司 | 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途 |
| US8932558B2 (en) * | 2007-10-05 | 2015-01-13 | Plaxgen Inc | Multi-subunit biological complexes for treatment of plaque-associated diseases |
| US20110294144A1 (en) * | 2008-02-12 | 2011-12-01 | Kenichi Noguchi | Screening method |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| CN102596221B (zh) * | 2009-06-10 | 2019-06-04 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| SI2625198T1 (sl) | 2010-10-07 | 2015-11-30 | Ac Immune S.A. Epfl Innovation Park | Protitelesa, ki prepoznavajo fosfo-tau |
-
2011
- 2011-07-14 GB GBGB1112056.5A patent/GB201112056D0/en not_active Ceased
-
2012
- 2012-07-16 EP EP12743696.2A patent/EP2731969B1/en active Active
- 2012-07-16 WO PCT/EP2012/063924 patent/WO2013007839A1/en not_active Ceased
- 2012-07-16 AU AU2012282402A patent/AU2012282402B2/en not_active Ceased
- 2012-07-16 US US14/232,659 patent/US9447179B2/en active Active
- 2012-07-16 JP JP2014519581A patent/JP6168364B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523742A5 (enExample) | ||
| TWI719894B (zh) | 抗原結合分子類和使用彼等之方法 | |
| CA3109036C (en) | Human immunodeficiency virus (hiv)-neutralizing antibodies | |
| Zhou et al. | Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2 | |
| CN111978398B (zh) | 针对冠状病毒sars-cov-2的抗体及其医学用途 | |
| JP2024156662A (ja) | 抗可変ｍｕｃ１＊抗体およびその使用 | |
| JP2022516039A (ja) | 抗ｃｄ１９抗体のモノクローナル抗体及びその使用 | |
| KR20220018479A (ko) | 동종이계 car-t 세포, 이의 제조 및 응용 | |
| WO2025015726A1 (zh) | 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用 | |
| AU2022213494A9 (en) | Therapeutic and diagnostic agents and uses thereof | |
| KR20220129026A (ko) | 아밀로이드 제거를 위한 키메라 항원 수용체 | |
| JP2024514477A (ja) | Ｓａｒｓ－ｃｏｖ－２抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法 | |
| Yu et al. | Specificity of recombinant antibodies generated from multiple sclerosis cerebrospinal fluid probed with a random peptide library | |
| WO2015199618A1 (en) | Epstein-barr virus lmp2 specific antibody and uses thereof | |
| CN113667011B (zh) | 制备抗原结合单元的方法 | |
| WO2023026207A1 (en) | Potently neutralizing novel human monoclonal antibodies against sars-cov-2 (covid-19) | |
| WO2024036204A2 (en) | Modified antibodies and methods of use thereof | |
| US9340601B2 (en) | Splice variants of the EGF receptor | |
| KR20160093723A (ko) | 새로운 항 adam17 항체 및 암의 치료를 위한 그의 용도 | |
| CN118667005A (zh) | 抗pd-l1的纳米抗体及其用途 | |
| CN111892657B (zh) | 用于检测米田堡血型抗原的抗体及其片段、试剂盒及方法 | |
| JP2018150260A (ja) | インフルエンザウイルスの増殖を阻害するモノクローナル抗体 | |
| US20250250359A1 (en) | Terminal deoxynucleotidyl transferase antibodies and uses thereof | |
| Brackenridge et al. | Mapping the epitopes of the Human Leukocyte Antigen E antibodies 3D12 and 4D12 | |
| HK40064555A (en) | Method for providing antigen binding units |